Matches in Wikidata for { <http://www.wikidata.org/entity/Q66046389> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q66046389 description "clinical trial" @default.
- Q66046389 description "ensayu clínicu" @default.
- Q66046389 description "klinisch onderzoek" @default.
- Q66046389 description "клінічне випробування" @default.
- Q66046389 name "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 name "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 type Item @default.
- Q66046389 label "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 label "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 prefLabel "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 prefLabel "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects" @default.
- Q66046389 P1050 Q66046389-1822BD03-037A-411B-A945-08CB237E990E @default.
- Q66046389 P1132 Q66046389-A798F18C-E972-4A04-81D3-F19146CC5344 @default.
- Q66046389 P1476 Q66046389-C0BD352C-98F9-4C2D-9A24-282EA30B58E9 @default.
- Q66046389 P17 Q66046389-28AEF4BE-00DA-4A6A-B0FD-030E532B1DAC @default.
- Q66046389 P17 Q66046389-777C575B-DCFC-4C79-BBCA-0D24E3D2852F @default.
- Q66046389 P17 Q66046389-9CF76C5D-FD69-43BE-A686-AF983D6ECEEF @default.
- Q66046389 P17 Q66046389-C4CD43C4-007C-4688-AEBB-E1DB571BA2B1 @default.
- Q66046389 P17 Q66046389-D39DDD8F-FA11-448B-AAB9-D517006B44A2 @default.
- Q66046389 P2899 Q66046389-8F988996-7200-49CA-90DD-C793F63DC230 @default.
- Q66046389 P3098 Q66046389-78FAE89F-4FE2-42B3-8D65-1CBBA89A10EA @default.
- Q66046389 P31 Q66046389-59E62C4C-9114-4D7F-9DF5-80B9391E004C @default.
- Q66046389 P4844 Q66046389-C333F050-E83A-42BB-AEDF-FFE12A7ACA7A @default.
- Q66046389 P580 Q66046389-736C2ADC-C86E-47E3-BE82-C4A31FB3FA7E @default.
- Q66046389 P582 Q66046389-434D2EA6-6CDB-4ADB-8B45-7490F3149B48 @default.
- Q66046389 P6099 Q66046389-F4524D6B-E98F-420B-B293-61209A73177C @default.
- Q66046389 P8363 Q66046389-4225C753-08EA-415C-A606-C85C583A3ECB @default.
- Q66046389 P1050 Q12206 @default.
- Q66046389 P1132 "+386" @default.
- Q66046389 P1476 "A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin" @default.
- Q66046389 P17 Q17 @default.
- Q66046389 P17 Q28 @default.
- Q66046389 P17 Q29 @default.
- Q66046389 P17 Q30 @default.
- Q66046389 P17 Q36 @default.
- Q66046389 P2899 "+18" @default.
- Q66046389 P3098 "NCT03115112" @default.
- Q66046389 P31 Q30612 @default.
- Q66046389 P4844 Q19484 @default.
- Q66046389 P580 "2017-10-12T00:00:00Z" @default.
- Q66046389 P582 "2018-07-11T00:00:00Z" @default.
- Q66046389 P6099 Q42824827 @default.
- Q66046389 P8363 Q78089383 @default.